Trials / Completed
CompletedNCT04547894
A Study of the Pharmacokinetics of ASC09F in Healthy Subjects
A Study to Evaluate the Pharmacokinetics of ASC09F in Healthy Subjects After Multiple Doses
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to evaluate the pharmacokinetic parameters of ASC09F in healthy subjects after multiple oral dosing.
Detailed description
This study will evaluate the safety and the pharmacokinetics of ASC09F tablets in healthy volunteers. Subjects will receive 7 days multiple oral doses of ASC09F tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC09F | ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days. |
Timeline
- Start date
- 2020-11-09
- Primary completion
- 2020-12-07
- Completion
- 2020-12-07
- First posted
- 2020-09-14
- Last updated
- 2021-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04547894. Inclusion in this directory is not an endorsement.